Search

Introduction: The aim of this study was to determine whether baseline right ventricular (RV) function assessed by standard echocardiography may indicate patients who will respond to cardiac resynchronization therapy (CRT)., Material and Methods: The data of 57 patients (54 men, 95%), aged 66.4 ±8.7 years with heart failure (HF) having a CRT device implanted were collected. All patients had left ventricular ejection fraction (LVEF) ≤ 35% and QRS complex duration ≥ 120 ms. Echocardiographic examination with tissue Doppler imaging techniques and complex RV evaluation were performed at baseline and three months after CRT onset., Results: Three months after CRT implantation, patients responding to CRT, defined as a reduction of left ventricle end-systolic volume (LVESV) of at least 10% (n = 34), compared to patients with a reduction of LVESV of less than 10% (n = 23), had at baseline a smaller right atrium diameter (47.85 ±11.33 mm vs. 52.65 ±8.69 mm; p = 0.028), higher TAPSE (14.56 ±2.57 mm vs. 13.04 ±2.93 mm; p = 0.030) and lower grade of tricuspid valve regurgitation (1.82 ±0.97 vs. 2.3 ±0.88; p = 0.033)., Conclusions: This study showed that there are differences in baseline right ventricular function between responders and non-responders to CRT. Yet in our study, none of the baseline RV parameters provided any value in identifying patients who would respond to CRT.

Background: Chronic heart failure (CHF) is a serious public health problem associated with high rates of morbidity and mortality. Cardiac resynchronisation therapy (CRT) is a well established treatment for selected patients who do not respond to optimal drug treatment of CHF., Aim: To assess the impact of CRT on the physical ability and quality of life (QoL) of patients with CHF., Methods: The study group consisted of 60 patients (mean age: 66.3 ± 8.7 years, 57 males and three females) with CHF classified as NYHA class III or IV (despite optimal pharmacotherapy for more than three months), a left ventricular end-diastolic diameter ≥ 55 mm, ejection fraction (LVEF) ≤ 35%, and a QRS duration ≥ 130 ms. Just before CRT, and three months after the procedure, patients were assessed using echocardiography and the 6-minute walk test (6-MWT), while their QoL was assessed by the Psychological General Well-Being index (PGWB). Three months after CRT, a 10% increase in baseline values of the 6-MWT constituted a positive response - patients who improved in this manner were classified as responders. Changes of at least ± 10% from baseline values of the PGWB total index were considered as improvement or worsening in QoL., Results: During the follow-up, three men died, and so 57 patients were included in the final analysis. At the end of the study, an increase in the walking distance during the 6-MWT (298.0 ± 107.4 m vs 373.1 ± 127.2 m; p 〈 0.001) was observed. After three months, 38 (66.7%) patients were classified as responders while 19 (33.3%) subjects were classified as non-responders to CRT. Concurrently, after CRT we observed an improvement in QoL in 34 (59.6%) patients, while 23 (41.4%) patients showed no such effect. Patients who demonstrated an increased QoL at three months after CRT were characterised by lower baseline values of the total PGWB index as well as its dimensions (with the exception of the general health dimension). Improvement in QoL after CRT was observed only in the responders group (p 〈 0.01)., Conclusions: The implementation of CRT leads to a reduction of heart failure related symptoms and an increase in physical ability in roughly two thirds of patients. Improvement in QoL after CRT pertains only to patients who demonstrate simultaneously an improvement in their 6-MWT. None of the other baseline clinical and echocardiographic parameters were useful in predicting better QoL and exercise capacity after CRT implementation.

Background and Aim: The aim of this study was to evaluate the short term effect of cardiac resynchronisation therapy (CRT) on right ventricular (RV) function assessed by standard echocardiography., Methods: Data from 57 patients (54 men, 95%; three women, 5%), aged 66.4 ± 8.7 years with heart failure (HF) was analysed. All patients were in NYHA III-IV functional classes, despite optimal pharmacological treatment according to the current guidelines, had left ventricular ejection fraction ≤ 35% and QRS complex ≥ 120 ms in a standard electrocardiogram. At baseline and three months after CRT implantation the patients' histories were taken, an anthropometrical examination was made, laboratory tests including the level of NT-proBNP and electrocardiogram were performed, and echocardiographic examination was extended by tissue Doppler imaging techniques and complex RV evaluation., Results: Three months after CRT implantation in the whole study group, the average NYHA functional class had decreased from 3.11 ± 0.28 to 2.25 ± 0.68 (p < 0.001), and the six-minute walk test distance had increased from 298.04 ± 107.42 m to 373.12 ± 127.15 m (p < 0.001). CRT improved RV systolic function in the whole study group. Tricuspid annular plane systolic excursion had increased from 13.95 ± 2.80 to 15.79 ± 2.33 mm (p < 0.001), and so likewise had systolic excursion velocity (S'), which rose from 8.84 ± 3.45 to 11.00 ± 3.43 cm/s (p < 0.001). Tricuspid regurgitation grade decreased from 2.02 ± 0.95 to 1.86 ± 0.91 (p = 0.013). RV systolic pressure decreased from 31.07 ± 20.43 to 27.75 ± 17.35 mm Hg (p < 0.001). RV fractional area change rose from 31.35 ± 10.30% to 35.40 ± 10.51% (p < 0.001)., Conclusions: This study showed that CRT improved RV systolic function evaluated with parameters assessed in standard echocardiographic examination three months after therapy initiation. The observed improvement was consistent among all applied echocardiographic parameters reflecting RV systolic function.

The role of hypercholesterolemia as a risk factor for cardiovascular disease has been well-documented. Hypercholesterolemia is the most prevalent modifiable risk factor in Poland. Despite the fact that the benefits of cholesterol lowering have been known for a long time, the therapeutic goals recommended by guidelines are still often not attained in clinical practice. Only 3% of Poles with hypercholesterolemia achieve recommended cholesterol levels, and the rate of reaching recommended goals among patients receiving lipid-lowering drugs is low, approximately 30%. Control of hypercholesterolemia is not satisfactory also in patients with ischemic heart disease. The introduction of new statins, use of higher statin doses, and the evidence pointing to the effectiveness of combination therapy have provided us with effective tools whose broad application in everyday practice may lead to a significant improvement in the control of hypercholesterolemia in Poland.

Background: Sleep-related breathing disorders are common in patients with chronic heart failure (CHF) and contribute to exacerbation of CHF. The effects of biventricular stimulation (CRT) seem to exceed the improvement of mechanical heart performance and are likely to affect other aspects of CHF pathophysiology. The aim of the study was to assess the influence of CRT on subjective and objective sleep features., Material and Methods: Twenty seven consecutive patients (aged 67.7 +/- 8.7 years, 23 men - 85%) with chronic heart failure (62.9% with ischaemic background and 37.1% of non-ischaemic etiology) in stable for at least 3 months NYHA class III - IV despite optimized pharmacotherapy, with left ventricular end-diastolic diameter (LVEDd) > 55 mm, left ventricular ejection fraction (LVEF) < or = 35% and wide QRS complex (> or = 120 ms) were appraised before and 12-16 weeks after CRT introduction clinically (including 6-minute walk test--6-MWT), echocardiographically and in polisomnography. The apnea-hypopnea index (AHI) and apnea indexes (AI) of central, obstructive and mixed types were calculated. The sleep quality was assessed with the Pittsburgh Sleep Quality Index (PSQI), daytime sleepiness with the Epworth Sleepiness Scale (ESS)., Results: LVEF increased, 6-MWT distance rose. Left ventricular diameters and left ventricular end-systolic volume decreased. PQSI and ESS fell (9.3 +/- 4.2 vs 6.2 +/- 3.2, p < 0.001 and 8.4 +/- 4.1 vs 7.0 +/- 3.4, p < 0.001, respectively). AHI, obstructive AL and mixed AL did not alter but significant reduction of central AL was noted (9.6 +/- 13.0 vs 3.7 +/- 6.2, p = 0.023)., Conclusions: CRT decreases central sleep apnea and improves quality of sleep and daytime sleepiness in patients with CHF.

Background: Solid evidence shows that cardiac resynchronization therapy (CRT) improves prognosis, physical capacity and quality of life in selected groups of patients with chronic heart failure (CHF). Nonetheless, marked percentage of patients seem not to benefit from CRT., Material and Methods: Sixty consecutive patients (aged 66.3 +/- 8.7 years, 57 men - 95%, 3 women - 5%) with CHF (71.7% with ischaemic and 28,3% with non-ischaemic origin) of stable for > or = 3 months NYHA III or IV class despite optimized pharmacotherapy, with left ventricle end-diastolic diameter (LVEDd) > or = 55 mm, left ventricular ejection fraction (EF) < or = 35% and QRS > 130 ms were evaluated before and 3 months after CRT implementation (biventricular stimulation BiV) echocardiographically and clinically., Results: EF increased (21.7% vs 26,6%, p<0,0001), 6-minute walk distance (6-MWT) rose (298.0 m vs 373.1 m, p<0,0001), left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV) decreased (244.3 ml vs 226,4 ml, p=0.0002; 192.8 ml vs 168,7 ml, p<0,0001 respectively). Mean NYHA class dropped from 3.1 to 2.2 (p<0.0001). Absolute increase in EF of > or = 4%, > or = 5%, > or = 6% was observed in 63.2%, 52.6%, and 35.7% respectively; relative increase of > or = 25% presented 21.1%, > or = 10% reduction of LVESV--59.7%, > or = 15% reduction of LVESV--43.8%, decrease in NYHA class--78.3%, > or = 10% reduction of 6-MWT--66.7%, no death and no hospitalization due to heart failure--78.3%., Conclusions: Response to CRT rate differs markedly according to the applied definition.